Actuate Therapeutics Inc
actuatetherapeutics.comWhat Do They Do?
Develops elraglusib, an experimental cancer drug, for patients with hard-to-treat cancers.
10-K for FY2025, filed Mar 26, 2026We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$4.9MView ↗
- ▼ −18% (Loss)
- vs −$5.9M in Q2 FY2025
-
Jul 17, 2026
Nasdaq notified the company of a continued-listing deficiency
The company has until January 11, 2027 to regain compliance or could face delisting.
Sources
8-K, filed Jul 17, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days from the date of the Notice, or through January 11…View ↗
Who Do They Compete With?
Competes with Revolution Medicines, Arcus Biosciences, Ipsen Pharma, Panbela Therapeutics, Astellas, Alligator Pharmaceuticals, Immuneering, Lisata Therapeutics, Theriva Biologics, and Oncolytics Biotech
10-K for FY2025, filed Mar 26, 2026Several other targeted therapies are also being evaluated in Phase 3 in mPDAC. The panRAS inhibitor daraxonrasib (RMC-6236, Revolution…View ↗
Loading...
